EGTXS Stock Overview
A pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Egetis Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 6.95 |
| 52 Week High | SEK 0 |
| 52 Week Low | SEK 0 |
| Beta | 1.43 |
| 11 Month Change | 0% |
| 3 Month Change | 28.14% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -19.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| EGTXS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 2.2% |
| 1Y | n/a | -17.9% | 8.8% |
Return vs Industry: Insufficient data to determine how EGTXS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how EGTXS performed against the UK Market.
Price Volatility
| EGTXS volatility | |
|---|---|
| EGTXS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: EGTXS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine EGTXS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 34 | Nicklas Westerholm | www.egetis.com |
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a highly debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020.
Egetis Therapeutics AB (publ) Fundamentals Summary
| EGTXS fundamental statistics | |
|---|---|
| Market cap | SEK 1.34b |
| Earnings (TTM) | -SEK 319.40m |
| Revenue (TTM) | SEK 70.80m |
19.0x
P/S Ratio-4.2x
P/E RatioIs EGTXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EGTXS income statement (TTM) | |
|---|---|
| Revenue | SEK 70.80m |
| Cost of Revenue | SEK 206.50m |
| Gross Profit | -SEK 135.70m |
| Other Expenses | SEK 183.70m |
| Earnings | -SEK 319.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 08, 2024
| Earnings per share (EPS) | -1.09 |
| Gross Margin | -191.67% |
| Net Profit Margin | -451.13% |
| Debt/Equity Ratio | 27.1% |
How did EGTXS perform over the long term?
See historical performance and comparison